Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 26c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. CL
5. TFII
6. LYB
7. LITE
8. NVT
9. SPY
10. AAPL

Go back to Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 26c

Jazz Pharmaceuticals Announces Third Quarter 2018 Financial Results

November 6, 2018 4:05 PM EST

DUBLIN, Nov. 6, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2018 and updated financial guidance for 2018.

"We delivered strong top-line and bottom-line growth in the third quarter and recently achieved two significant regulatory milestones, with the receipt of marketing authorization for Vyxeos in the EU and FDA approval of Xyrem for pediatric narcolepsy patients," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "In the U.S., we are reinforcing Vyxeos as essential therapy for secondary AML with... More